## Cathy Hammerman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8257477/publications.pdf

Version: 2024-02-01

121 papers 4,498 citations

36 h-index 110387 64 g-index

129 all docs

 $\begin{array}{c} 129 \\ \\ \text{docs citations} \end{array}$ 

times ranked

129

3695 citing authors

#	Article	IF	CITATIONS
1	Safety assessment of probiotics for human use. Gut Microbes, 2010, 1, 164-185.	9.8	513
2	Oral Probiotics Prevent Necrotizing Enterocolitis in Very Low Birth Weight Neonates. Journal of Pediatrics, 2005, 147, 192-196.	1.8	503
3	Ductal Closure With Paracetamol: A Surprising New Approach to Patent Ductus Arteriosus Treatment. Pediatrics, 2011, 128, e1618-e1621.	2.1	191
4	Hyperbilirubinemia, hemolysis, and increased bilirubin neurotoxicity. Seminars in Perinatology, 2014, 38, 429-437.	2.5	128
5	The effects of maternal age and parity on maternal and neonatal outcome. Archives of Gynecology and Obstetrics, 2015, 291, 793-798.	1.7	121
6	Neonatal Hyperbilirubinemia in Glucose-6-Phosphate Dehydrogenase-deficient Heterozygotes. Pediatrics, 1999, 104, 68-74.	2.1	119
7	Decreased lipid intake reduces morbidity in sick premature neonates. Journal of Pediatrics, 1988, 113, 1083-1088.	1.8	110
8	Infants With Bilirubin Levels of 30 mg/dL or More. Pediatrics, 2004, 113, 429-430.	2.1	105
9	Imbalance Between Production and Conjugation of Bilirubin: A Fundamental Concept in the Mechanism of Neonatal Jaundice. Pediatrics, 2002, 110, e47-e47.	2.1	104
10	Paracetamol for the treatment of patent ductus arteriosus in preterm neonates: a systematic review and meta-analysis. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2016, 101, F127-F136.	2.8	103
11	Severe Neonatal Hyperbilirubinemia and Kernicterus: Are These Still Problems in the Third Millennium?. Neonatology, 2011, 100, 354-362.	2.0	89
12	Glucose-6-phosphate dehydrogenase deficiency: A hidden risk for kernicterus. Seminars in Perinatology, 2004, 28, 356-364.	2.5	83
13	Hyperbilirubinemia Among African American, Glucose-6-Phosphate Dehydrogenase-Deficient Neonates. Pediatrics, 2004, 114, e213-e219.	2.1	76
14	Prolonged indomethacin therapy for the prevention of recurrences of patent ductus arteriosus. Journal of Pediatrics, 1990, 117, 771-776.	1.8	69
15	CONTRIBUTION OF HAEMOLYSIS TO JAUNDICE IN SEPHARDIC JEWISH GLUCOSEâ€6â€PHOSPHATE DEHYDROGENASE DEFICIENT NEONATES. British Journal of Haematology, 1996, 93, 822-827.	2.5	67
16	Conjugated bilirubin in neonates with glucose-6-phosphate dehydrogenase deficiency. Journal of Pediatrics, 1996, 128, 695-697.	1.8	66
17	Indomethacin Tocolysis Increases Postnatal Patent Ductus Arteriosus Severity. Pediatrics, 1998, 102, e56-e56.	2.1	66
18	Gilbert's syndrome and hyperbilirubinaemia in ABO-incompatible neonates. Lancet, The, 2000, 356, 652-653.	13.7	65

#	Article	IF	Citations
19	The silent ductus: Its precursors and its aftermath. Pediatric Cardiology, 1986, 7, 121-127.	1.3	62
20	Understanding severe hyperbilirubinemia and preventing kernicterus: Adjuncts in the interpretation of neonatal serum bilirubin. Clinica Chimica Acta, 2005, 356, 9-21.	1.1	61
21	Population-based trends in mortality and neonatal morbidities among singleton, very preterm, very low birth weight infants over 16 years. Early Human Development, 2014, 90, 821-827.	1.8	59
22	Bilirubin Genetics for the Nongeneticist: Hereditary Defects of Neonatal Bilirubin Conjugation. Pediatrics, 2003, 111, 886-893.	2.1	58
23	Predischarge Bilirubin Screening in Glucose-6-Phosphate Dehydrogenase-Deficient Neonates. Pediatrics, 2000, 105, 533-537.	2.1	57
24	Acute hemolysis and severe neonatal hyperbilirubinemia in glucose-6-phosphate dehydrogenase–deficient heterozygotes. Journal of Pediatrics, 2001, 139, 137-140.	1.8	54
25	Hemolysis and Hyperbilirubinemia in Antiglobulin Positive, Direct ABO Blood Group Heterospecific Neonates. Journal of Pediatrics, 2010, 157, 772-777.	1.8	54
26	Hemolysis and bilirubin conjugation in association with UDP-glucuronosyltransferase 1A1 promoter polymorphism. Hepatology, 2002, 35, 905-911.	7.3	50
27	Neonatal Screening for Glucose-6-Phosphate Dehydrogenase Deficiency: Biochemical Versus Genetic Technologies. Seminars in Perinatology, 2011, 35, 155-161.	2.5	50
28	Managing the Patent Ductus Arteriosus in the Premature Neonate: A New Look at What We Thought We Knew. Seminars in Perinatology, 2012, 36, 130-138.	2.5	49
29	Amelioration of Ischemia-Reperfusion Injury in Rat Intestine by Pentoxifylline-Mediated Inhibition of Xanthine Oxidase. Journal of Pediatric Gastroenterology and Nutrition, 1999, 29, 69-74.	1.8	49
30	Bilirubin in the Premature: Toxic Waste or Natural Defense?. Clinical Chemistry, 1998, 44, 2551-2553.	3.2	46
31	Glucose-6-phosphate dehydrogenase deficiency: a potential source of severe neonatal hyperbilirubinaemia and kernicterus. Seminars in Fetal and Neonatal Medicine, 2002, 7, 121-128.	2.7	46
32	Prostanoids in neonates with persistent pulmonary hypertension. Journal of Pediatrics, 1987, 110, 470-472.	1.8	44
33	N-terminal pro-B-type Natriuretic Peptide as a Marker of Bronchopulmonary Dysplasia in Premature Infants. American Journal of Perinatology, 2010, 27, 381-386.	1.4	44
34	Neonatal hyperbilirubinemia in African American males: The importance of glucose-6-phosphate dehydrogenase deficiency. Journal of Pediatrics, 2006, 149, 83-88.	1.8	38
35	Ibuprofen Versus Continuous Indomethacin in Premature Neonates With Patent Ductus Arteriosus: Is the Difference in the Mode of Administration?. Pediatric Research, 2008, 64, 291-297.	2.3	38
36	Germ warfare: probiotics in defense of the premature gut. Clinics in Perinatology, 2004, 31, 489-500.	2.1	37

#	Article	IF	CITATIONS
37	Quantitative Neonatal Glucose-6-Phosphate Dehydrogenase Screening: Distribution, Reference Values, and Classification by Phenotype. Journal of Pediatrics, 2012, 161, 197-200.	1.8	37
38	Probiotics and neonatal intestinal infection. Current Opinion in Infectious Diseases, 2006, 19, 277-282.	3.1	35
39	(TA)n UGT 1A1 Promoter Polymorphism: A Crucial Factor in the Pathophysiology of Jaundice in G-6-PD Deficient Neonates. Pediatric Research, 2007, 61, 727-731.	2.3	35
40	Immature sucking patterns in infants of mothers with diabetes. Journal of Pediatrics, 2006, 149, 640-643.	1.8	34
41	Evaluation of Discharge Management in the Prediction of Hyperbilirubinemia: The Jerusalem Experience. Journal of Pediatrics, 2007, 150, 412-417.	1.8	33
42	Rapid Fecal Calprotectin (FC) Analysis: Point of Care Testing for Diagnosing Early Necrotizing Enterocolitis. American Journal of Perinatology, 2015, 32, 337-342.	1.4	33
43	Differing Pathogenesis of Perinatal Bilirubinemia in Glucose-6-Phosphate Dehydrogenase-Deficient Versus-Normal Neonates. Pediatric Research, 2001, 50, 532-537.	2.3	32
44	The Effect of Meconium Staining of Amniotic Fluid on the Growth of Escherichia coli and Group B Streptococcus. Journal of Perinatology, 2002, 22, 467-471.	2.0	32
45	Bilirubin and the Genome: The Hereditary Basis of Unconjugated Neonatal Hyperbilirubinemia. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2005, 3, 21-42.	0.3	30
46	Comparative Tolerability of Pharmacological Treatments for Patent Ductus Arteriosus. Drug Safety, 2001, 24, 537-551.	3.2	29
47	Understanding and preventing severe neonatal hyperbilirubinemia: is bilirubin neurotoxity really a concern in the developed world?. Clinics in Perinatology, 2004, 31, 555-575.	2.1	29
48	Failure of Prophylactic Indomethacin to Improve the Outcome of the Very Low Birth Weight Infant. Developmental Pharmacology and Therapeutics, 1987, 10, 393-404.	0.2	26
49	(TA)n UDP-Glucuronosyltransferase 1A1 Promoter Polymorphism in Nigerian Neonates. Pediatric Research, 2008, 63, 109-111.	2.3	26
50	Tale of Two Patent Ductus Arteriosus Severity Scores: Similarities and Differences. American Journal of Perinatology, 2018, 35, 055-058.	1.4	23
51	Upper Lip Tie and Breastfeeding: A Systematic Review. Breastfeeding Medicine, 2019, 14, 83-87.	1.7	23
52	Femoral Hypoplasia – Unusual Facies Syndrome: Prenatal Ultrasonographic Observations. Fetal Diagnosis and Therapy, 1993, 8, 279-284.	1.4	22
53	Prediction of Hyperbilirubinemia in Near-Term and Term Infants. Journal of Perinatology, 2001, 21, S63-S72.	2.0	22
54	Studies in hemolysis in glucose-6-phosphate dehydrogenase-deficient African American neonates. Clinica Chimica Acta, 2006, 365, 177-182.	1.1	22

#	Article	IF	CITATIONS
55	Low Levels of Procalcitonin During Episodes of Necrotizing Enterocolitis. Digestive Diseases and Sciences, 2007, 52, 2972-2976.	2.3	22
56	Intravenous lipids in newborn lungs. Critical Care Medicine, 1989, 17, 430-436.	0.9	21
57	Glucose-6-phosphate dehydrogenase activity in term and near-term, male African American neonates. Clinica Chimica Acta, 2005, 355, 113-117.	1.1	21
58	Very low-birth-weight-infants conceived by in vitro fertilization are not at higher risk for mortality and morbidity: a population-based study. Fertility and Sterility, 2006, 85, 907-912.	1.0	21
59	Third Ventricle Enlargement Among Newborn Infants With Trisomy 21. Pediatrics, 2006, 117, e928-e931.	2.1	21
60	SMOFlipid Protects Preterm Neonates against Perinatal Nutrition–Associated Cholestasis. American Journal of Perinatology, 2019, 36, 1382-1386.	1.4	20
61	Failure to Predict Hemolysis and Hyperbilirubinemia by IgG Subclass in Blood Group A or B Infants Born to Group O Mothers. Pediatrics, 2009, 123, e132-e137.	2.1	19
62	Prostaglandin levels: Predictors of indomethacin responsiveness. Pediatric Cardiology, 1986, 7, 61-65.	1.3	18
63	N-terminal-Pro-B-Type Natriuretic Peptide in Premature Patent Ductus Arteriosus: A Physiologic Biomarker, But Is It a Clinical Tool?. Pediatric Cardiology, 2010, 31, 62-65.	1.3	18
64	Effects of Hyperventilation on Prostacyclin Formation and on Pulmonary Vasodilation after Group B $\hat{l}^2$ -Hemolytic Streptococci-Induced Pulmonary Hypertension. Pediatric Research, 1991, 29, 282-287.	2.3	17
65	Patent Ductus Arteriosus in the Premature Neonate. Paediatric Drugs, 1999, 1, 81-92.	3.1	17
66	Direct Antiglobulin Titer Strength and Hyperbilirubinemia. Pediatrics, 2014, 134, e1340-e1344.	2.1	16
67	Elevated Nucleated Red Blood Cells at Birth Predict Hemodynamically Significant Patent Ductus Arteriosus. Journal of Pediatrics, 2016, 177, 313-315.	1.8	14
68	Paracetamol Serum Concentrations in Neonates Treated Enterally for Ductal Closure: A Pilot Study. Journal of Pediatrics, 2018, 198, 304-307.	1.8	14
69	Hypocalcemia and the patent ductus arteriosus. Journal of Pediatrics, 1979, 94, 961-963.	1.8	13
70	Indomethacin and apnea of prematurity. Critical Care Medicine, 1993, 21, 154-155.	0.9	13
71	Hyperbilirubinaemia, glucose-6-phosphate dehydrogenase deficiency and Gilbert syndrome. European Journal of Pediatrics, 2001, 160, 195-195.	2.7	13
72	Neonatal Hyperbilirubinemia in the Low-Intermediate–Risk Category on the Bilirubin Nomogram. Pediatrics, 2012, 130, e470-e475.	2.1	13

#	Article	lF	CITATIONS
73	The Preterm Infant. Clinics in Perinatology, 2016, 43, 325-340.	2.1	13
74	Selective Inhibition of Thromboxane Synthetase Reduces Group-B-Beta-Hemolytic-Streptococci-Induced Pulmonary Hypertension in Piglets. Developmental Pharmacology and Therapeutics, 1988, 11, 306-312.	0.2	12
75	The mortality of very low birth weight infants: the benefit and relative impact of changes in population and therapeutic variables. Journal of Maternal-Fetal and Neonatal Medicine, 2019, 32, 2443-2451.	1.5	11
76	Indomethacin and retinopathy of prematurity: The hidden paradox. Journal of Pediatrics, 2008, 153, 587-588.	1.8	10
77	Glucose-6-Phosphate Dehydrogenase Screening in Israel-Arab and Palestinian-Arab Neonates. Journal of Pediatrics, 2015, 167, 169-172.	1.8	10
78	Might Bilirubin Serve as a Natural Antioxidant in Response to Neonatal Encephalopathy?. American Journal of Perinatology, 2018, 35, 1107-1112.	1.4	10
79	Prostaglandins and echocardiography in the assessment of patent ductus arteriosus. Critical Care Medicine, 1986, 14, 462-465.	0.9	9
80	Head Circumference Growth Is Enhanced by SMOFlipid in Preterm Neonates. American Journal of Perinatology, 2020, 37, 1130-1133.	1.4	9
81	Heterozygosity for a polymorphism in the promoter region of the UGT1A1 gene. Journal of Hepatology, 2001, 35, 148-149.	3.7	8
82	Neonatal Polycythemia and Hypoglycemia in Newborns: Are They Related?. American Journal of Perinatology, 2021, 38, 930-934.	1.4	7
83	Infant delivery and maternal stress during the COVID-19 pandemic: a comparison of the well-baby versus neonatal intensive care environments. Journal of Perinatology, 2021, 41, 2614-2620.	2.0	7
84	Severe Hyponatremia with Indomethacin A More Serious Toxicity than Previously Realized?. Developmental Pharmacology and Therapeutics, 1985, 8, 260-267.	0.2	6
85	OXYGEN TRANSPORT IN NEWBORN PIGLETS WITH PULMONARY HYPERTENSION. Critical Care Medicine, 1988, 16, 773-778.	0.9	6
86	Comparative Effects of Two Phototherapy Delivery Systems on Cerebral Blood Flow Velocity in Term Neonates. Neonatology, 2004, 86, 254-258.	2.0	6
87	Twin Pregnancy in a Patient after the Fontan Operation: Report of a Case. Congenital Heart Disease, 2013, 8, E196-E198.	0.2	6
88	Elevated Nucleated Red Blood Cells in Neonates with Down Syndrome and Pulmonary Hypertension. Journal of Pediatrics, 2019, 213, 232-234.	1.8	6
89	Hyperbilirubinemia in the Term Infant. Clinics in Perinatology, 2021, 48, 533-554.	2.1	5
90	Endogenous dilator prostaglandins in congenital heart disease. Pediatric Cardiology, 1987, 8, 155-159.	1.3	4

#	Article	IF	Citations
91	Primum non nocere: prophylactic versus curative ibuprofen. Lancet, The, 2004, 364, 1920-1922.	13.7	4
92	Ductus arteriosus outcome with focus on the initially patent but hemodynamically insignificant ductus in preterm neonates. Journal of Perinatology, 2018, 38, 1526-1531.	2.0	4
93	Effect of rewarming in oxygenation and respiratory condition after neonatal exposure to moderate therapeutic hypothermia. Pediatrics and Neonatology, 2019, 60, 423-427.	0.9	4
94	Indomethacin and the Cardiopulmonary Adaptations of Transition. Pediatric Research, 1984, 18, 842-845.	2.3	3
95	Packed red blood cells transfusion in neonates: effect on FiO2 and PaO2/SaO2 ratio, and implications for neonatal saturation targeting. Journal of Perinatology, 2018, 38, 693-695.	2.0	3
96	Wide Pulse Pressure Is Not Associated with Patent Ductus Arteriosus in the First Week of Life. American Journal of Perinatology, 2019, 36, 1401-1404.	1.4	3
97	Variations in local PGE levels: A potential factor in therapeutic responsiveness?. Pediatric Cardiology, 1991, 12, 74-77.	1.3	2
98	Screening for glucose-6-phosphate dehydrogenase deficiency. Journal of Pediatrics, 1992, 121, 165-166.	1.8	2
99	Prophylactic ibuprofen in premature infants: a multicentre, randomised, double-blind, placebo-controlled trial. Journal of Pediatrics, 2005, 146, 709-710.	1.8	2
100	Hyperbilirubinemia in black infants. Journal of Pediatrics, 2013, 163, 611.	1.8	2
101	Surrogate Outcomes: An Inevitable Limitation of Hyperbilirubinemia-Driven Randomized Controlled Trials. Neonatology, 2020, 117, 694-696.	2.0	2
102	Dual Therapy vs. Monotherapy for the Patent Ductus Arteriosus: A Systematic Review. Pediatric Cardiology, 2022, 43, 935-942.	1.3	2
103	Asphyxia-Related Infant Mortality Rates. American Journal of Perinatology, 1994, 11, 290-294.	1.4	1
104	Reply:. Hepatology, 2002, 36, 764-765.	7.3	1
105	Association between neonatal hyperbilirubinemia and <scp>UDP</scp> â€glucuronosyltransferase <i>1<scp>A</scp>1</i> gene polymorphisms. Pediatrics International, 2013, 55, 259-259.	0.5	1
106	Early neonatal pyloric stenosis after exposure to maternal macrolide therapy. Case Reports in Perinatal Medicine, 2016, 5, 135-137.	0.1	1
107	Mandatory closure versus nonintervention for patent ductus arteriosus in very preterm infants. Journal of Pediatrics, 2017, 182, 406.	1.8	1
108	The use of intramuscular glucagon to prevent IV glucose infusion in early neonatal hypoglycemia. Journal of Perinatology, 2021, 41, 1158-1165.	2.0	1

#	Article	IF	CITATIONS
109	Early breast expression for very low birth infants admitted to neonatal intensive care unit: the challenges of cesarean deliveries. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 8249-8256.	1.5	1
110	Mildly Elevated Bilirubin Levels are Associated with Increased Magnetic Resonance Imaging Signal Intensity in the Basal Ganglia of Preterm Neonates. American Journal of Perinatology, 2021, , .	1.4	1
111	Heparinization of Long Indwelling Lines in Neonates: Systematic Review and Practical Recommendations. Israel Medical Association Journal, 2016, 18, 692-696.	0.1	1
112	A simple noninvasive biomarker can reflect both the acute and chronic pulmonary impact of patent ductus arteriosus Ashunting. Pediatric Pulmonology, 2022, 57, 1209-1213.	2.0	1
113	Letters to the editor. Indian Journal of Pediatrics, 2008, 75, 192-194.	0.8	0
114	Use of Oxyhemoglobin Saturation or Oxygen Tensionâ€"An Unsolved Question. JAMA Pediatrics, 2018, 172, 390.	6.2	0
115	Trends in Drug Trial Publications Involving Neonates: Has the Legislation Helped?. American Journal of Therapeutics, 2019, 26, e714-e716.	0.9	0
116	Familial Hyperbilirubinemia in ABO-Incompatible Neonates. Pediatrics, 2003, 112, 1453-1454.	2.1	0
117	Onset of jaundice in G6PD deficient neonates. Indian Pediatrics, 2006, 43, 459-61; author reply 461.	0.4	0
118	The Saga of Pulse Oximetry Screening for Critical Congenital Heart Disease in Israel: A Historical Perspective. Israel Medical Association Journal, 2021, 23, 229-232.	0.1	0
119	Hypercapnia: An Added Culprit in Gray Matter Injury in Preterm Neonates. Neuropediatrics, 2022, , .	0.6	0
120	Does Early Neonatal Thrombocytopenia Affect Ductal Therapeutic Response to Acetaminophen in Preterm Neonates?. American Journal of Perinatology, 2022, 29, 1519-1523.	1.4	0
121	Mitral valve Doppler for cardiac output assessment in preterm neonates. Echocardiography, 2022, 39, 717-723.	0.9	O